Hyperbaric oxygen has the strongest evidence for radiation cystitis in a 69-study review

Across 69 studies of late urinary toxicity after pelvic RT, hyperbaric oxygen had the strongest evidence for radiation cystitis; surgical outcomes remained heterogeneous.

KEY POINTS

  • This scoping review from Trinity College Dublin evaluated contemporary management strategies for late urinary complications following pelvic radiotherapy. A PRISMA-ScR-guided search of PubMed and Embase identified 69 distinct studies represented by 70 publications, covering literature published between January 2015 and April 2026. The evidence included only two randomized controlled trials, alongside 58 retrospective studies and nine prospective observational cohorts. Management approaches were organized into 24 bladder-preserving, 28 reconstructive, and 17 salvage or end-stage studies.
  • Hyperbaric oxygen therapy (HBOT) had the strongest comparative evidence for chronic radiation cystitis. In the randomized RICH-ART trial, 87 patients were randomized and 79 analyzed, receiving either standard care or 30–40 HBOT sessions with 100% oxygen at approximately 240–250 kPa for 80–90 minutes per session. At 6–8 months, mean EPIC urinary score improved by 17.8 points with HBOT versus 7.7 with standard care, corresponding to a 10.1-point between-group difference (95% CI 2.2–18.1; p=0.013). Cystoscopic improvement was also more frequent with HBOT (64% vs 18%; p=0.0012).
  • Long-term HBOT outcomes suggested durable symptom improvement, but randomized comparison was not maintained. Following the randomized RICH-ART endpoint, control patients could receive HBOT, and the five-year analysis followed 70 HBOT-treated patients from both original groups. Among 39 patients with five-year data, mean EPIC urinary score remained 19.1 points above the pre-HBOT baseline (95% CI 13.3–24.9; p<0.0001), while 12.8% required additional HBOT for recurrent symptoms. Observational data were broadly supportive, including one 105-patient cohort reporting 92.4% hemorrhage control, although 24.7% subsequently experienced recurrence.
  • Other bladder-preserving approaches showed potential benefits but substantially weaker evidence. A randomized trial of intravesical sodium hyaluronate involving 58 evaluable patients reported improvements in hematuria and bladder pain relative to saline, with quality-of-life benefits emerging during follow-up. Small observational studies also supported hyaluronic acid combined with chondroitin sulfate, laser coagulation, and selected intravesical hemostatic therapies. However, recurrence, persistent storage symptoms, and subsequent need for surgery remained important limitations, and the heterogeneity of treatment indications prevented reliable comparative ranking.
  • Reconstructive surgery often restored urinary tract patency but carried important functional consequences. In a multicenter series of 137 men undergoing excision and primary anastomosis urethroplasty after prostate irradiation, 86.9% achieved instrumentation-free voiding at a mean follow-up of 32.3 months. However, 32.1% developed stress incontinence requiring more than one pad daily, 21.9% subsequently received an artificial urinary sphincter, and 16.7% of sphincter cuffs eroded. In a separate 79-patient series of dorsal buccal mucosal graft urethroplasty, 82.3% achieved anatomical success, with de novo stress incontinence in 8.1% of previously continent men.
  • Management of radiation-associated ureteral strictures depended strongly on anatomical complexity. A multicenter cohort of 53 patients reported 74% initial success with endourological treatment, decreasing to 59% overall success during follow-up, while robotic reconstruction achieved 96% success in the selected surgical population. In the largest reconstructive series, involving 192 women with distal ureteral strictures after gynecological RT, surgical reimplantation or Boari flap reconstruction achieved patency rates of approximately 95.5–100%, depending on technique. These findings demonstrate that reconstruction can be effective, but the treatments were applied to different anatomical problems and cannot be compared as randomized alternatives.
  • Severe radiation-related urinary injury sometimes required definitive urinary diversion or cystectomy. Across 17 salvage/end-stage studies, surgery frequently reduced pelvic pain, opioid requirements, bleeding, hospital admissions, and repeated procedures, but Clavien grade ≥3a complications occurred in approximately 28–35% of several major surgical cohorts. Interpretation of the broader literature was limited by incomplete RT reporting: only 56% of publications specified RT modality, 33% reported total dose or fractionation, and 70% provided the interval from irradiation to subsequent toxicity or intervention. The review was narrative rather than a meta-analysis, and even the HBOT randomized trial was judged at high risk of bias because patient-reported outcomes were assessed in an unblinded design.

CLINICAL TAKEAWAY

For chronic radiation cystitis, hyperbaric oxygen has the most substantial evidence supporting bladder-preserving symptom improvement, whereas management of radiation-induced strictures, incontinence, fistulas, and end-stage injury relies largely on retrospective specialist-center experience. Treatment selection should be guided by the specific urinary syndrome, anatomical severity, tissue quality, functional consequences, and patient preferences, with early multidisciplinary referral when repeated conservative interventions fail.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction